4-butyrolactone has been researched along with cgp 35348 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernasconi, R; Bittiger, H; Lauber, J; Leonhardt, T; Marescaux, C; Martin, P; Reymann, N; Rubio, V; Vergnes, M | 1 |
| Waldmeier, PC | 1 |
| Fukuda, H; Ishige, K; Ito, Y | 1 |
| Banerjee, PK; Brailowsky, S; Olsen, RW; Snead, OC; Tillakaratne, NJ; Tobin, AJ | 1 |
| Carter, LP; Chen, W; Coop, A; France, CP; Koek, W; Lamb, RJ; Wu, H | 1 |
| Carter, LP; Coop, A; France, CP; Koek, W; Wu, H | 1 |
| Coop, A; Koek, W; Mercer, SL | 1 |
| Cabras, C; Carai, MA; Colombo, G; Gessa, GL; Lobina, C; Maccioni, P | 1 |
| Baker, LE; Poling, A; Pynnonen, DM; Searcy, GD | 1 |
| Aleem, IS; Ashraf, A; Cortez, MA; Kanawaty, A; Liu, CC; Sadeghnia, HR; Shen, L; Snead, OC; Stewart, L; Trepanier, CH; Wu, Y | 1 |
| Coop, A; France, CP; Koek, W; Mercer, SL | 1 |
11 other study(ies) available for 4-butyrolactone and cgp 35348
| Article | Year |
|---|---|
Experimental absence seizures: potential role of gamma-hydroxybutyric acid and GABAB receptors.
Topics: 4-Butyrolactone; Animals; Baclofen; Brain; Cyclic GMP; Disease Models, Animal; Epilepsy, Absence; GABA-A Receptor Antagonists; Male; Organophosphorus Compounds; Rats; Rats, Inbred Strains; Receptors, GABA-A; Reference Values; Reproducibility of Results; Sodium Oxybate; Valproic Acid | 1992 |
The GABAB antagonist, CGP 35348, antagonizes the effects of baclofen, gamma-butyrolactone and HA 966 on rat striatal dopamine synthesis.
Topics: 4-Butyrolactone; Animals; Baclofen; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; GABA-A Receptor Antagonists; Haloperidol; Organophosphorus Compounds; Pyrrolidinones; Rats; Tetrabenazine | 1991 |
Pharmacological profiles of absence seizure-induced increases in CRE- and AP-1 DNA-binding activities in gamma-butyrolactone-treated mice.
Topics: 4-Butyrolactone; Activating Transcription Factor 2; Animals; Anticonvulsants; Brain; Brain Chemistry; Cerebral Cortex; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; DNA-Binding Proteins; Epilepsy, Absence; Ethosuximide; GABA Antagonists; Mice; Organophosphorus Compounds; Phosphinic Acids; Thalamus; Transcription Factor AP-1; Transcription Factors | 1998 |
Alterations in GABAA receptor alpha 1 and alpha 4 subunit mRNA levels in thalamic relay nuclei following absence-like seizures in rats.
Topics: 4-Butyrolactone; Animals; Epilepsy, Absence; GABA Antagonists; GABA Modulators; Gene Expression; Hippocampus; In Situ Hybridization; Male; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; RNA, Messenger; Thalamus; Time Factors | 1998 |
Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam.
Topics: 4-Butyrolactone; Anesthetics, Intravenous; Animals; Baclofen; Benzocycloheptenes; Benzylamines; Butylene Glycols; Diazepam; Discrimination, Psychological; Dithiothreitol; Dose-Response Relationship, Drug; GABA Agonists; GABA Antagonists; GABA Modulators; GABA-B Receptor Agonists; GABA-B Receptor Antagonists; Male; Organophosphorus Compounds; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Sodium Oxybate | 2005 |
Discriminative stimulus effects of flumazenil: perceptual masking by baclofen, and lack of substitution with gamma-hydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone.
Topics: 4-Butyrolactone; Animals; Baclofen; Benzocycloheptenes; Butylene Glycols; Columbidae; Discrimination, Psychological; Dose-Response Relationship, Drug; Flumazenil; GABA Agonists; GABA Antagonists; GABA Modulators; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; GABA-B Receptor Agonists; GABA-B Receptor Antagonists; Organophosphorus Compounds; Sodium Oxybate | 2006 |
Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348.
Topics: 4-Butyrolactone; Animals; Baclofen; Catalepsy; Dose-Response Relationship, Drug; GABA Agonists; GABA Antagonists; GABA-B Receptor Agonists; Male; Mice; Mice, Inbred C57BL; Narcolepsy; Organophosphorus Compounds; Receptors, GABA-B; Sodium Oxybate; Substance-Related Disorders | 2007 |
Gamma-aminobutyric acidB (GABAB)-receptor mediation of different in vivo effects of gamma-butyrolactone.
Topics: 4-Butyrolactone; Animals; Benzocycloheptenes; GABA Antagonists; GABA-B Receptor Antagonists; Hypnotics and Sedatives; Hypothermia; Male; Mice; Mice, Inbred DBA; Morpholines; Motor Activity; Organophosphorus Compounds; Prodrugs; Receptors, GABA-B; Reflex; Solvents | 2008 |
Differentiating the discriminative stimulus effects of gamma-hydroxybutyrate and ethanol in a three-choice drug discrimination procedure in rats.
Topics: 4-Butyrolactone; Animals; Baclofen; Benzocycloheptenes; Butylene Glycols; Discrimination, Psychological; Ethanol; Flunitrazepam; GABA Agonists; GABA Antagonists; GABA Modulators; Ketamine; Male; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, N-Methyl-D-Aspartate; Sodium Oxybate | 2008 |
Infantile spasms and Down syndrome: a new animal model.
Topics: 4-Butyrolactone; Animals; Anticonvulsants; Baclofen; Brain; Disease Models, Animal; Down Syndrome; Electroencephalography; Ethosuximide; GABA Agonists; Genotype; Humans; Infant; Mice; Mice, Mutant Strains; Organophosphorus Compounds; Phenotype; Receptors, GABA-A; Receptors, GABA-B; Spasms, Infantile; Time Factors; Valproic Acid; Vigabatrin | 2009 |
Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348).
Topics: 4-Butyrolactone; Anesthetics, Intravenous; Animals; Baclofen; Columbidae; Conditioning, Operant; Dose-Response Relationship, Drug; GABA Agonists; GABA Antagonists; GABA-B Receptor Agonists; GABA-B Receptor Antagonists; Injections, Intramuscular; Kinetics; Organophosphorus Compounds; Sodium Oxybate | 2009 |